Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
As regenerative therapies for blinding diseases move closer to clinical trials, the NEI's functional imaging consortium is pioneering noninvasive technologies to monitor the function of the retina’s neurons and their connections to the brain.
Researchers at the University of Wisconsin have developed a micro-molded scaffolding photoreceptor “patch” designed to be implanted under a damaged or diseased retina.
More than 20 years after the launch of a landmark clinical trial, follow-up examinations and analyses found that not all patients with elevated eye pressure need pressure-lowering treatment to prevent vision loss from glaucoma.
A new study showed that ingesting the compound citicoline restored optic nerve (neural) signals between the brain and eye to near-normal levels in the study rats.
A gene therapy protects eye cells in mice with a rare disorder that causes vision loss, especially when used in combination with other gene therapies, shows a study published in eLife.
LambdaVision, the Farmington, Connecticut-based biotech firm that developed the artificial retina, is exploring optimizing production of an artificial retina in space, in a series of missions to the International Space Station.
Using laboratory-grown roundworms as well as human and mouse eye tissue, researchers have identified a new potential mechanism for age-related macular degeneration—the leading cause of blindness among older adults.
Scientists at the University of Pennsylvania School of Veterinary Medicine report findings of a gene therapy to treat a severe form of Leber congenital amaurosis, caused by mutations in the NPHP5 gene.